Search results for " IVIG"
Article
Report from the Eighth International Plasma Product Biotechnology Meeting Melia Salinas, Lanzarote, Spain
During the meeting the outbreak of thromboembolic events (TEE’s), causing IVIG product withdrawal some years ago, was still discussed. However, compared to the previous meeting in 2010 the perception …
Article
From Darwin to Recombinant Fc Multimers
Forrest covered the R&D contribution to a tech transfer for the IVIg Privigen® process from Switzerland to Australia. This included a secondment of an R&D employee to Switzerland, to be actively invol…
Article
A Bright Future for the Plasma Fractionation Industry
Philippe Paoloantonnacci presented a QbD approach for a new LFB IVIg product, with identification of Product Quality Attributes (PQAs) and Critical Quality Attributes (CQAs). Process risk analysis was…
Article
Report from the 12th Plasma Product Biotechnology Forum
It was the consensus that immunoglobulins will remain as the key driver for plasma fractionation market, and even if alternative therapies are getting stronger, they will not totally replace IVIG (int…
Article
Leveraging Computational Models of Glycosylation for Biopharma QA
Close collaboration between academic and industrial groups is vital to ensuring glycosylation models are fit for deployment.
By Ioscani Jiménez del Val
Good Studio/S…